EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Assessment of advanced glycation end-products as a biomarker of diabetic outcomes

Olga Simó-Servat, Alejandra Planas, Andreea Ciudin, Rafael Simó, Cristina Hernández

Endocrinología, Diabetes y Nutrición · 2018-11 · 65 (9) · 540-545

DOI: 10.1016/j.endinu.2018.06.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinología, Diabetes y Nutrición, 2018-11. Verfasst von Olga Simó-Servat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfe…. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: European Foundation for the Study of Diabetes, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are substantial differences in the onset and severity of diabetes complications that are not fully explained by HbA1c levels and other risk factors. HbA1c is the gold standard for assessing metabolic control, but has limited value to identify patients at risk of developing diabetic complications. The main disadvantage of HbA1c is that it does not provide information about glycemic variability and does not reflect long-term exposure to hyperglycemia. One of the main pathogenetic mechanisms of diabetic complications is the generation and accumulation of advanced glycation end-products (AGEs). Based on its fluorescence properties, AGEs may be measured in tissues such as the skin or lens. These non-invasive measurements of AGE accumulation may be considered as promising biomarkers of late diabetic complications, and our objective is to summarize the available evidence supporting this statement. However, further translational research and prospective clinical trials are needed before these new biomarkers may be incorporated into clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersDiabetes ComplicationsForecastingGlycated HemoglobinGlycation End Products, AdvancedHumans

Stichwörter der Autor:innen

Advanced glycation end-productsBiomarcadorBiomarkerComplicacionesComplicationsDiabetesProductos avanzados de la glicación

Substanzen

BiomarkersGlycated HemoglobinGlycation End Products, Advanced

Autor:innen und Institutionen

  • Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain. Electronic address:…
  • Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute Barcelona, Spain.
  • Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain.

Förderung

  • European Foundation for the Study of Diabetes
  • Instituto de Salud Carlos III

Zitieren

APA

Simó-Servat, O., Planas, A., Ciudin, A., Simó, R., & Hernández, C. (2018). Assessment of advanced glycation end-products as a biomarker of diabetic outcomes. Endocrinología, Diabetes y Nutrición, 65(9), 540-545. https://doi.org/10.1016/j.endinu.2018.06.003

Vancouver

Simó-Servat O, Planas A, Ciudin A, Simó R, Hernández C. Assessment of advanced glycation end-products as a biomarker of diabetic outcomes. Endocrinología, Diabetes y Nutrición. 2018;65(9):540-545. doi:10.1016/j.endinu.2018.06.003

BibTeX
@article{SimServat2018,
  author = {Simó-Servat, Olga and Planas, Alejandra and Ciudin, Andreea and Simó, Rafael and Hernández, Cristina},
  title = {Assessment of advanced glycation end-products as a biomarker of diabetic outcomes},
  journal = {Endocrinología, Diabetes y Nutrición},
  year = {2018},
  volume = {65},
  number = {9},
  pages = {540--545},
  doi = {10.1016/j.endinu.2018.06.003}
}
Kostenlos starten →